What's Going On With Kiora Pharmaceuticals Stock?

Comments
Loading...
Zinger Key Points
  • TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments up to approximately $285 million.
  • Kiora Pharmaceuticals also enters into a securities purchase agreement with certain institutional investors.
  • Get Monthly Picks of Market's Fastest Movers

Kiora Pharmaceuticals, Inc. KPRX shares are trading higher Thursday after the company announced a private placement of up to $45 million and an exclusive license and development agreement with Théa Open Innovation SAS (TOI).

The Details:

According to an SEC filing, TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments totaling up to approximately $285 million, upon and subject to the achievement of certain specified clinical development, regulatory and commercial milestones.

In addition, Kiora is eligible to receive tiered royalties of between a high single digit to low twenty percent range based on a specified percentage of net sales.

Kiora Pharmaceuticals also entered into a securities purchase agreement with certain institutional investors, pursuant to which Kiora agreed to issue and sell 15,800,000 shares and warrants for expected aggregate gross proceeds at closing of approximately $15 million and potential future warrant exercise gross proceeds of approximately $30 million.

Related News: What’s Going On With Rivian Automotive Stock?

KPRX Stock Prediction 2024:

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Kiora Pharmaceuticals, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Kiora Pharmaceuticals, the 200-day moving average sits at $0.96, according to Benzinga Pro, which is above the current price of $0.78. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

KPRX Price Action: According to Benzinga Pro, Kiora Pharmaceutical shares are up 70% at 94 cents at the time of publication.

Image: Leopictures from Pixabay

Overview Rating:
Good
62.5%
Technicals Analysis
66
0100
Financials Analysis
60
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!